相关实验视频

Updated: Jul 7, 2025

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

针对癌症免疫治疗的ENPP1目标:用一石杀两只小鸟

Ruilei Huang¹, Qian Ning², Jihui Zhao¹

¹Hunan Province Key Laboratory for Antibody-Based Drug and Intelligent Delivery System, School of Pharmaceutical Sciences, Hunan University of Medicine, Huaihua 418000, China.

Biochemical pharmacology

|December 24, 2023

概括

向核酸核酸二酶1 (ENPP1) 可以通过促进T细胞反应来增强癌症免疫疗法. 抑制ENPP1会重新激活免疫系统来对抗瘤,改善患者的预后.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物化学生物化学

背景情况:

癌症免疫疗法的有效性受到瘤内T细胞反应不足的限制.
这种cGAS-STING通路对于先天性免疫激活和瘤清除至关重要.
瘤细胞过度表达ENPP1,它通过降解2',3'-cGAMP并促进腺的产生来抑制抗癌免疫力.

研究的目的:

审查ECTONUCLEOTIDE酸盐二酶1 (ENPP1) 在癌症免疫治疗中的作用.
剖析通过ENPP1.1调解的免疫抑制机制.
讨论开发ENPP1抑制剂以改善癌症治疗.

主要方法:

关于ENPP1功能和癌症抑制的文献综述.
分析ENPP1在瘤微环境中的作用.
讨论ENPP1抑制剂的临床前和临床发展.

主要成果:

过度表达ENPP1与癌症预后不佳相关.
抑制ENPP1会增加细胞外的2',3'-cGAMP水平.
抑制ENPP1会减少腺的产生,从而增强抗瘤免疫反应.

结论:

在瘤微环境中,ENPP1是关键的免疫抑制因子.
抑制ENPP1对增强癌症免疫疗法的显著前景.
ENPP1 抑制剂代表了癌症治疗的潜在新疗法策略.

关键词:

亚丁氨酸 (Adenosine) 是一种在 ENPP1 中使用.ENPP1 抑制剂的使用.免疫治疗是一种免疫疗法.cGAMPP 的情况.cGAS-STING 信号通道的信号通道

更多相关视频

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...